ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/10/2023
Voltar para busca
Dado oficial do USPTO
OMASS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
07/10/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
26/02/2020
Data de registro
10/08/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/08/2021
Última transação
10/08/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
FITZSIMONS, MICHAEL R
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
OMASS Therapeutics Limited
Representantes
Rebecca Liebowitz Venable LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparations for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; biopharmaceutical preparations for treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; chemical, biochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; reagents for medical use, namely reagents for in-vitro laboratory use cells for medical or clinical use, namely cells, cell lines, and cell cultures for use in the production of proteins for therapeutic use; reagents for medical use; biological reagents for medical use; therapeutic antibodies; vaccines
Classe 42
Scientific and technological services, namely scientific research and development; laboratory research services in the field of chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; medical and pharmacological research services; scientific research, namely, analysis and measurement of substances; analysis and measurement of molecules and characteristics; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research; research and development in the fields of immunology, genetic conditions, oncology, immuno-oncology, ophthalmology, haematology, neurology, respiratory diseases, metabolic conditions, infectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnology research; biotechnology research, namely, biotechnology testing; chemical research and analysis; research and development of new products for others in the biotechnical, biomedical and pharmaceutical fields; research and development in the pharmaceutical field; research and development of vaccines and medicines; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical research, development and testing services; drug discovery services; drug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; research and development of molecules for therapeutic purposes; consultancy, advisory and/or information services in relation to all the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/02/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/01/2022
FIMP
FINAL DISPOSITION PROCESSED
24/01/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/11/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
10/08/2021
GPNX
NOTIFICATION PROCESSED BY IB
30/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/05/2021
PUBO
PUBLISHED FOR OPPOSITION
25/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/05/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/05/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/05/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/04/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/04/2021
DOCK
ASSIGNED TO EXAMINER
29/03/2021
RFNT
REFUSAL PROCESSED BY IB
22/11/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/11/2020
RFRR
REFUSAL PROCESSED BY MPU
02/11/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/10/2020
MAFR
APPLICATION FILING RECEIPT MAILED
10/10/2020
CNRT
NON-FINAL ACTION WRITTEN
09/10/2020
DOCK
ASSIGNED TO EXAMINER
06/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OMASS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.